Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEZS Aeterna Zentaris	$3.29 +21.8%	$3.57	$3.96 ▼ $12.00	$5.90M	1.55	7,305 shs	93,792 shs
AYTU Aytu BioPharma	$2.20 +0.9%	$2.29	$0.95 ▼ $2.85	$19.76M	0.13	112,448 shs	93,694 shs
CING Cingulate	$4.19 +5.0%	$4.55	$3.02 ▼ $11.88	$22.67M	-0.74	163,104 shs	131,694 shs
FNCH Finch Therapeutics Group	$13.48	$12.77	$10.15 ▼ $15.85	$21.65M	1.19	2,237 shs	66 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEZS Aeterna Zentaris	0.00%	+15.38%	-16.96%	-7.37%	-46.79%
AYTU Aytu BioPharma	0.00%	-0.45%	-16.35%	+12.24%	-9.84%
CING Cingulate	0.00%	+3.71%	-23.82%	+14.48%	-56.76%
FNCH Finch Therapeutics Group	0.00%	+6.14%	+7.41%	+3.69%	+17.22%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AEZS Aeterna Zentaris	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AYTU Aytu BioPharma	3.1266 of 5 stars	3.5	2.0	0.0	3.4	0.0	0.0	0.6
CING Cingulate	2.4351 of 5 stars	3.5	3.0	0.0	0.0	2.1	0.8	0.6
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AEZS Aeterna Zentaris	0.00	N/A	N/A	N/A
AYTU Aytu BioPharma	3.00	Buy	$10.00	354.55% Upside
CING Cingulate	3.00	Buy	$26.25	526.49% Upside
FNCH Finch Therapeutics Group	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest AEZS, FNCH, CING, and AYTU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	CING Cingulate	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$61.00 ➝ $62.00
8/8/2025	CING Cingulate	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/1/2025	AYTU Aytu BioPharma	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
6/30/2025	AYTU Aytu BioPharma	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
5/27/2025	CING Cingulate	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$60.00 ➝ $61.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AEZS Aeterna Zentaris	$2.37M	2.48	N/A	N/A	$14.99 per share	0.22
AYTU Aytu BioPharma	$81M	0.24	N/A	N/A	$4.64 per share	0.47
CING Cingulate	N/A	N/A	N/A	N/A	$2.32 per share	N/A
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	$14.25 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AEZS Aeterna Zentaris	-$16.55M	-$14.86	N/A	∞	N/A	-760.32%	-83.45%	-45.76%	N/A
AYTU Aytu BioPharma	-$15.84M	-$0.72	N/A	∞	N/A	2.37%	3.51%	0.91%	9/25/2025 (Estimated)
CING Cingulate	-$15.55M	-$4.10	N/A	N/A	N/A	N/A	-232.16%	-132.07%	11/6/2025 (Estimated)
FNCH Finch Therapeutics Group	-$74.75M	-$8.82	N/A	∞	N/A	N/A	-69.14%	-26.92%	N/A

Latest AEZS, FNCH, CING, and AYTU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/19/2025	Q2 2025	CING Cingulate	-$0.82	-$1.09	-$0.27	-$1.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AEZS Aeterna Zentaris	N/A	N/A	N/A	N/A	N/A
AYTU Aytu BioPharma	N/A	N/A	N/A	N/A	N/A
CING Cingulate	N/A	N/A	N/A	N/A	N/A
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AEZS Aeterna Zentaris	N/A	5.94	5.93
AYTU Aytu BioPharma	0.27	1.03	0.87
CING Cingulate	N/A	1.52	1.52
FNCH Finch Therapeutics Group	N/A	3.87	3.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AEZS Aeterna Zentaris	0.73%
AYTU Aytu BioPharma	33.49%
CING Cingulate	41.31%
FNCH Finch Therapeutics Group	21.77%

Insider Ownership

Company	Insider Ownership
AEZS Aeterna Zentaris	0.10%
AYTU Aytu BioPharma	3.60%
CING Cingulate	4.04%
FNCH Finch Therapeutics Group	44.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AEZS Aeterna Zentaris	20	1.79 million	1.79 million	No Data
AYTU Aytu BioPharma	160	8.98 million	8.65 million	Not Optionable
CING Cingulate	20	5.41 million	5.19 million	Not Optionable
FNCH Finch Therapeutics Group	190	1.61 million	885,000	No Data

AEZS, FNCH, CING, and AYTU Headlines

Recent News About These Companies

FNCH - Finch Therapeutics Group Inc Price vs Fair Value - Morningstar

July 4, 2025 | morningstar.comM

FNCH Finch Therapeutics Group, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

Arquitos Capital's Largest Holdings For Q1 2025

May 1, 2025 | seekingalpha.com

Arquitos Capital Management Q4 2024 Commentary

February 5, 2025 | seekingalpha.com

Finch Therapeutics Group, Inc.: Finch Announces Delisting from Nasdaq and SEC Deregistration

October 23, 2024 | finanznachrichten.de

Finch Therapeutics announces Nasdaq delisting, SEC deregistration

October 22, 2024 | markets.businessinsider.com

Finch Therapeutics Group to Delist from Nasdaq

October 22, 2024 | markets.businessinsider.com

Finch Announces Delisting from Nasdaq and SEC Deregistration

October 21, 2024 | globenewswire.com

Finch Therapeutics Gr (OTC:FNCH) Stock Quotes, Forecast and News Summary

October 5, 2024 | benzinga.com

Finch wins US jury trial against Ferring over fecal-transplant patents

August 10, 2024 | reuters.com

It is likely that Finch Therapeutics Group Inc (FNCH) Stock will grow up

May 25, 2024 | bovnews.comB

Finch Therapeutics Group (NASDAQ: FNCH)

April 14, 2024 | fool.com

Jeffery A. Smisek Sells 6,642 Shares of Finch Therapeutics Group, Inc. (NASDAQ:FNCH) Stock

March 31, 2024 | insidertrades.com

FNCH Stock Earnings: Finch Therapeutics Gr Reported Results for Q4 2023

March 25, 2024 | investorplace.com

Finch Therapeutics Group Inc (FNCH)

March 7, 2024 | investing.com

Finch Therapeutics Gr Stock (NASDAQ:FNCH), Short Interest Report

February 22, 2024 | benzinga.com

Finch Therapeutics Group Inc FNCH

November 5, 2023 | morningstar.comM

Analysts Are Bullish on These Healthcare Stocks: Nuvation Bio (NUVB), Finch Therapeutics Group (FNCH)

August 21, 2023 | markets.businessinsider.com

Finch Therapeutics Group, Inc.: Finch Announces Reverse Stock Split of Common Stock

June 9, 2023 | finanznachrichten.de

HC Wainwright & Co. Reiterates Finch Therapeutics Group (FNCH) Buy Recommendation

May 13, 2023 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AEZS, FNCH, CING, and AYTU Company Descriptions

Aeterna Zentaris NASDAQ:AEZS

$3.29 +0.59 (+21.79%)

As of 08/22/2025

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

Aytu BioPharma NASDAQ:AYTU

$2.20 +0.02 (+0.92%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.19 -0.01 (-0.45%)

As of 08/22/2025 07:46 PM Eastern

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Cingulate NASDAQ:CING

$4.19 +0.20 (+5.01%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$4.14 -0.05 (-1.07%)

As of 04:02 AM Eastern

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Finch Therapeutics Group NASDAQ:FNCH

$13.48 0.00 (0.00%)

As of 08/22/2025

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time